Silica-Shell Microcapsules for Tretinoin and Benzoyl Peroxide Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Topical retinoids like tretinoin and benzoyl peroxide, when used together, face stability issues due to oxidation, leading to reduced efficacy, and existing microencapsulation technologies have not yielded commercial products effectively addressing this problem.
Innovation Solution
Development of microcapsules with a core containing tretinoin in a solid form at high concentration, encapsulated by a silicon dioxide shell, using a specific process that includes forming an emulsion and adjusting pH, to stabilize tretinoin and benzoyl peroxide for simultaneous application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tretinoin and benzoyl peroxide are applied together in conventional formulations, then the treatment effectiveness for acne and rosacea is improved, but tretinoin undergoes oxidation and degradation reducing its stability and efficacy
Solution Approach 1:
The formulation is segmented into separate microcapsule systems: tretinoin is encapsulated in silica microcapsules while benzoyl peroxide remains free in the formulation. This physical separation prevents direct interaction between the two active ingredients, allowing them to be applied simultaneously without oxidation while maintaining individual therapeutic effects
Solution Approach 2:
Silica microcapsules serve as an intermediary barrier between tretinoin and benzoyl peroxide. The microcapsules protect tretinoin from oxidation by benzoyl peroxide while still allowing the combination formulation to provide synergistic treatment benefits for acne and rosacea
2Stability of the object's composition
If microencapsulation technology is used to protect tretinoin from oxidation, then tretinoin stability is improved, but manufacturing complexity and process difficulty increase
Solution Approach 1:
The patent utilizes specific parameter ranges for microcapsule preparation including pH 2-7, silica precursor concentrations of 0.1-10% w/v, and curing temperatures of 25-100°C. These optimized parameters simplify the manufacturing process while ensuring stable tretinoin encapsulation with high encapsulation efficiency
Solution Approach 2:
Silica microcapsules are formed as a composite structure with a silica shell encapsulating tretinoin core. This composite material approach provides stable encapsulation while using readily available materials and straightforward sol-gel chemistry, reducing overall manufacturing complexity
3Reliability
If high concentration of tretinoin is encapsulated in microcapsules, then treatment efficacy is improved, but microencapsulation efficiency and process control become more difficult
Solution Approach 1:
The patent achieves high encapsulation efficiency for concentrated tretinoin (0.01-10% w/w) by optimizing critical parameters including maintaining pH 2-7 during encapsulation, using silica precursor concentrations of 0.1-10% w/v, and controlling curing temperature at 25-100°C. These parameter optimizations enable precise control even at high active ingredient concentrations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microcapsules maintain high microencapsulation efficiency and stability, allowing concurrent use of tretinoin and benzoyl peroxide without significant degradation, effectively treating skin conditions like acne and rosacea.
Implementation Method 1
microcapsules comprising a core and a shell surrounding the core, wherein the core comprises tretinoin
Implementation Method 2
forming an emulsion and adjusting pH
Data Source
AI summary
The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.